Meanwhile, Creso’s Swiss division also performed equally strongly during the quarter, increasing by 1,600 per cent to $626k.
In March, Creso entered into an agreement to acquire Canada-based Halucencex Life Sciences. Halucencex is focused on developing novel psychedelic molecules to treat post-traumatic stress disorder , depression, and other mental illnesses.